Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
[16] DPP-4 inhibitors (such as sitagliptin), which enhance incretin activity through a different mechanism Insulin therapy, particularly if oral agents and other injectables are unsuitable Traditional agents like metformin, sulphonylureas, or pioglitazone, depending on individual circumstances NICE guideline NG28 recommends individualised treatment approaches based on HbA1c targets, cardiovascular risk, renal function, and patient preferences
Unexplained or debilitating fatigue
(Primary source for heart rate data) Ilkiw JL, Charman SA, Gao X, et al
Safety Considerations and Who Should Start at .25 mg The .25 mg dose is standard for treatment initiation across all populations due to its favorable gastrointestinal tolerability profile
Timeless favourites made contemporary
Florenzano P, Ferreira C, Nesterova G, Roberts MS, Tella SH, de Castro LF, Brown SM, Whitaker A, Pereira RC, Bulas D, Gafni RI, Salusky IB, Gahl WA, Collins MT (2018) Skeletal consequences of nephropathic cystinosis
